2026-17536Rule

DEA Adds Trip-Inducing Cipepofol to Schedule IV List

Published Date: 8/27/2026

Rule

Summary

On May 29, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Cypsedo (cipepofol) for induction of general anesthesia in adults undergoing surgery. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place cipepofol, chemically known as 2-[(1R)-1-cyclopropylethyl]-6- isopropylphenol, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing cipepofol in schedule IV of the CSA.

Analyzed Economic Effects

1 provisions identified: 0 benefits, 0 costs, 1 mixed.

Cipepofol Added to Schedule IV

The Drug Enforcement Administration is placing cipepofol (marketed as Cypsedo) into Schedule IV of the Controlled Substances Act effective August 27, 2026. The FDA approved Cypsedo on May 29, 2026, for induction of general anesthesia in adults undergoing surgery, and DEA concluded HHS recommended Schedule IV control based on abuse potential.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
Comments Due
8/27/2026
8/27/2026
9/28/2026

Department and Agencies

Department
Independent Agency
Agency
Justice Department
Drug Enforcement Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register